is being licensed to Australia’s Medicines Development for Global Health (MDGH), with Amgen surrendering all rights to the drug. The US biotech will continue to provide support for two phase 2 ...

Amgen’s stock has been rising consistently, with corrections in between due to pipeline setbacks. Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and ...

Amgen announced its plans to open a "technology and innovation" site in India last year that is focused on increasing the use of AI and data science to support development of new medicines.